Incannex Commences Screening for OSA Study
Incannex has started screening participants for its IHL-42X Phase 2 OSA trial. The company previously received FDA Fast Track designation for the drug.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day